Drug Trial Radar · NCT01416181
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
889
Actual
Start
Sep 13, 2011
Primary completion
Jul 28, 2015
Study completion Apr 13, 2016
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Aug 12, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 58 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2). Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objectives of Part 1 of this study are to determine the proportion of participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12), the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24 using magnetic resonance imaging (MRI) and the proportion of participants experiencing progression of disability as measured by individual physical Expanded Disability Status Scale (EDSS) system scores. Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of natalizumab in participants with SPMS. The secondary objectives of Part 2 of the study are to investigate long-term disability (based on clinical or participant-reported assessments) in participants with SPMS receiving natalizumab treatment for approximately 4 years and to assess change in brain volume and T2 lesion volume.
Conditions
- Secondary Progressive Multiple Sclerosis
Interventions
natalizumabDrug
Administered as specified in the treatment arm
PlaceboDrug
Matched placebo in part 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)Time frame: Up to 96 weeks (2 years)
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 218 weeks
Locations
161 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Fullerton, California
Research Site
Los Angeles, California
Research Site
Aurora, Colorado
Research Site
Tampa, Florida
Research Site
Chicago, Illinois
Research Site
Lake Barrington, Illinois
Research Site
Peoria, Illinois
Research Site
Indianapolis, Indiana
Research Site
Indianapolis, Indiana
Research Site
Kansas City, Kansas
Research Site
Lexington, Kentucky
Research Site
Lexington, Kentucky
Research Site
Baltimore, Maryland
Research Site
Burlington, Massachusetts
Research Site
Omaha, Nebraska
Research Site
Lebanon, New Hampshire
Research Site
Teaneck, New Jersey
Research Site
Latham, New York
Research Site
New York, New York
Research Site
Advance, North Carolina
Research Site
Charlotte, North Carolina
Research Site
Raleigh, North Carolina
Research Site
Akron, Ohio
Research Site
Uniontown, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Clackamas, Oregon
Research Site
Portland, Oregon
Research Site
Portland, Oregon
Research Site
Nashville, Tennessee
Research Site
Charlottesville, Virginia
Research Site
Seattle, Washington
Research Site
Green Bay, Wisconsin
Research Site
Milwaukee, Wisconsin
Research Site
La Louvière, Belgium
Research Site
Melsbroek, Belgium
Research Site
Overpelt, Belgium
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.